NCT00126074View on ClinicalTrials.gov

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Atrial FibrillationAtrial Flutter
Interventions
DRUG

Tedisamil sesquifumarate

Trial Locations (26)

Unknown

Site 26, Honolulu

Site 27, Tullahoma

Site 5, Pleven

Site 2, Sofia

Site 3, Sofia

Site 4, Sofia

Site 6, Sofia

Site 7, Sofia

Site 8, Mannheim

Site 11, Budapest

Site 12, Budapest

Site 14, Budapest

Site 15, Budapest

Site 9, Budapest

Site 13, Kecskemét

Site 10, Korhaz

Site 16, Piacenza

Site 22, Chrzanów

Site 20, Gdansk

Site 25, Gdynia

Site 19, Katowice

Site 18, Krakow

Site 24, Szczecin

Site 17, Tarnów

Site 23, Wałbrzych

Site 21, Zakopane

All Listed Sponsors
lead

Solvay Pharmaceuticals

INDUSTRY

NCT00126074 - Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects | Biotech Hunter | Biotech Hunter